Trial Profile
Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2022
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TERRA
- Sponsors Taiho Pharmaceutical Company
- 02 Jul 2022 Results of a network analysis of data pooled from 3 global (ReDOS, CORRECT, RECOURSE) and 3 Asian (TERRA, Yoshino 2012, and CONCUR) studies assessed the impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer presented at the 24th World Congress on Gastrointestinal Cancer
- 06 Sep 2019 According to a Taiho Pharmaceutical media release, based on the data from this trial, the China National Medical Products Administration (NMPA) has approved TAS-102 (trifluridine/tipiracil) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine, oxaliplatin- and irinotecan-based chemotherapy, in addition, might be treated or not able to be treated by an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
- 05 Feb 2018 Status changed from active, no longer recruiting to completed.